Collection of Blood and/or Bone Marrow for Investigation and Characterization of Normal and Abnormal Cell Growth
Verified March 2014 by University of Massachusetts, Worcester
Information provided by (Responsible Party):
Jan Cerny, University of Massachusetts, Worcester
First received: May 24, 2010
Last updated: March 7, 2014
Last verified: March 2014
The collection of Blood and/or Bone Marrow from patients with blood disorders, blood cell malignancies and associated conditions will serve as a convenient and comprehensive source of tissue to give us further information about the differences between normal blood cells and blood cells of affected individuals. This will be an invaluable asset for understanding the biology of blood disorders. The collected samples will be used by investigators for studies including immunology, molecular biology and genetics to name a few.
||Time Perspective: Prospective
||Collection of Blood and/or Bone Marrow for Investigation and Characterization of Normal and Abnormal Cell Growth in Patients With Malignancy or Hematologic Disorders
Primary Outcome Measures:
Biospecimen Retention: Samples Without DNA
Secondary Outcome Measures:
Tissue/cells from patients' samples.
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||December 2099 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Patients over the age of 18 with blood and/or bone disorders (leukemia, myeloproliferative disorders, lymphoma etc.) with alterations of their blood counts.
- Selected patients over the age of 18 with hematologic malignancies or other blood disorders (leukemia, myeloproliferative disorders, lymphoma, other malignancies involving the bone marrow or patients with unexplained alterations in their complete blood count).
Patients who are scheduled to undergo a bone marrow aspirate and/or phlebotomy for other clinical indications will be asked to participate. They will be asked to donate an additional small aliquot of bone marrow and/or blood during the course of their already scheduled bone marrow aspiration or phlebotomy.
- Patients with pre-existing medical conditions that might be exacerbated by the procedure of obtaining bone marrow or blood
- Patients who are allergic to Lidocaine, which is used as a local anesthetic, and who cannot receive a suitable substitute anesthetic.
- Patients who have a bleeding diathesis which might pose a problem with marrow aspiration.
- Patients unable to give informed consent.
- Pregnant patients
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01174615
|University of Massachusetts Medical School
|Worcester, Massachusetts, United States, 01655 |
|Contact: Jan Cerny, MD, PhD 774-442-3903 Jan.Cerny@umassmemorial.org |
|Contact: Stephen Lyle, MD, PhD 508-856-4774 Stephen.Lyle@umassmed.edu |
|Principal Investigator: Jan Cerny, MD, PhD |
University of Massachusetts, Worcester
||Jan Cerny, MD, PhD
||University of Massachusetts, Worcester
No publications provided
||Jan Cerny, Principal Investigator, University of Massachusetts, Worcester
History of Changes
|Other Study ID Numbers:
|Study First Received:
||May 24, 2010
||March 7, 2014
||United States: Institutional Review Board
Keywords provided by University of Massachusetts, Worcester:
Blood/bone marrow collection, hematologic diseases, leukemia
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on July 26, 2014
Neoplasms by Histologic Type